Skip to main content

Table 2 Survival outcomes for the surrogate endpoints at 2 and 3 years

From: Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone

Surrogate endpoint Events Survival rates a
NACT+CCRT group CCRT group Total, NACT+CCRT group, % CCRT group, % P-value *
(n = 104, %) (n = 104, %) No. (%)
At 2 years
 PFS 15 (14.4) 25 (24.0) 40 (29.2) 87 76 0.078
 FFS 14 (13.5) 22 (21.2) 36 (27.3) 87 79 0.134
 D-FFS 12 (11.5) 21 (20.2) 33 (15.9) 88 80 0.092
 LR-FFS 3 (2.9) 6 (5.8) 9 (4.3) 98 94 0.284
At 3 years
 PFS 19 (18.3) 31 (29.8) 50 (24.0) 83 72 0.049
 FFS 16 (15.4) 28 (26.9) 44 (21.2) 85 75 0.040
 D-FFS 12 (11.5) 25 (24.0) 37 (17.8) 88 77 0.022
 LR-FFS 5 (4.8) 9 (8.7) 14 (6.7) 95 92 0.235
  1. Abbreviations: CCRT concurrent chemoradiotherapy; D-FFS distant failure-free survival; FFS failure-free survival; LR-FFS locoregional failure-free survival; NACT neoadjuvant chemotherapy; PFS progression-free survival
  2. aThe survival rates for the surrogate endpoints were estimated using the Kaplan-Meier method
  3. *P-values were calculated using the log-rank test